tiprankstipranks
Advertisement
Advertisement

KYKOF Stock Latest News

Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
The FlyKura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
10d ago
KURA
Kyowa Kirin downgraded to Sell from Buy at Citi
PremiumThe Fly
Kyowa Kirin downgraded to Sell from Buy at Citi
2M ago
Kyowa Kirin downgraded to Underweight from Equal Weight at Morgan Stanley
PremiumThe Fly
Kyowa Kirin downgraded to Underweight from Equal Weight at Morgan Stanley
3M ago
Kyowa Kirin downgraded to Neutral from Outperform at SMBC Nikko
PremiumThe Fly
Kyowa Kirin downgraded to Neutral from Outperform at SMBC Nikko
3M ago
Kyowa Kirin downgraded to Underweight from Neutral at JPMorgan
PremiumThe Fly
Kyowa Kirin downgraded to Underweight from Neutral at JPMorgan
3M ago
Kyowa Kirin announces discontinuation of rocatinlimab clinical trials
PremiumThe FlyKyowa Kirin announces discontinuation of rocatinlimab clinical trials
3M ago
AMGN
KYKOF Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
KYKOF Upcoming Earnings Report: What to Expect?
3M ago
Kyowa Kirin to regain control of rocatinlimab development, commercialization
Premium
The Fly
Kyowa Kirin to regain control of rocatinlimab development, commercialization
4M ago
AMGN
Kyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
PremiumThe Fly
Kyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
5M ago
Kyowa Kirin’s Poteligeo Study: A Closer Look at Market Implications
PremiumCompany Announcements
Kyowa Kirin’s Poteligeo Study: A Closer Look at Market Implications
7M ago
KYKOF
Kyowa Kirin’s New Clinical Trial: A Potential Game-Changer in T-Cell Lymphoma Treatment
PremiumCompany Announcements
Kyowa Kirin’s New Clinical Trial: A Potential Game-Changer in T-Cell Lymphoma Treatment
7M ago
KYKOF
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
PremiumCompany Announcements
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
7M ago
KYKOF
Kyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
PremiumCompany AnnouncementsKyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
7M ago
KYKOF
Kyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia
Premium
Company Announcements
Kyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia
7M ago
KYKOF
Kyowa Kirin’s KK3910: A New Hope in Hypertension Treatment?
Premium
Company Announcements
Kyowa Kirin’s KK3910: A New Hope in Hypertension Treatment?
7M ago
KYKOF
Kyowa Kirin’s Phase 3 Trial on KK8398 for Achondroplasia: A Potential Game-Changer
PremiumCompany Announcements
Kyowa Kirin’s Phase 3 Trial on KK8398 for Achondroplasia: A Potential Game-Changer
7M ago
KYKOF
Kyowa Kirin’s Promising Study on KK2845 for Acute Myeloid Leukemia
PremiumCompany Announcements
Kyowa Kirin’s Promising Study on KK2845 for Acute Myeloid Leukemia
7M ago
KYKOF
Kyowa Kirin’s KK2260 Study: A Potential Game-Changer in Cancer Treatment?
PremiumCompany Announcements
Kyowa Kirin’s KK2260 Study: A Potential Game-Changer in Cancer Treatment?
7M ago
KYKOF
Kyowa Kirin’s KK2269 Study: A Potential Game-Changer in Solid Tumor Treatment?
PremiumCompany Announcements
Kyowa Kirin’s KK2269 Study: A Potential Game-Changer in Solid Tumor Treatment?
7M ago
KYKOF
Kura Oncology receives $30M development milestone payment for ziftomenib
PremiumThe FlyKura Oncology receives $30M development milestone payment for ziftomenib
7M ago
KURA
Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
Premium
The Fly
Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
8M ago
KURA
Kyowa Kirin’s Poteligeo Study: A Closer Look at Safety and Efficacy
Premium
Company Announcements
Kyowa Kirin’s Poteligeo Study: A Closer Look at Safety and Efficacy
9M ago
KYKOF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >